Fundz

Vyome Holdings

San Clemente, California, United States · Biotechnology, Health Care, Medical

Vyome is a clinical-stage healthcare holding company focusing on transformative therapies for patients with immuno-inflammatory conditions. They are building a premier platform spanning the US-India innovation corridor. Vyome aims to leverage its clinical-stage assets to create shareholder value in a cost-efficient manner.

Key facts

Headquarters
San Clemente, California, United States
Employees
19
Industries
Biotechnology, Health Care, Medical
Status
Public (HIND)
Website
www.vyometx.com
LinkedIn
Company page

Recent activity at Vyome Holdings

  • : Vyome Appoints Jerry Leonard as Chief Financial Officer
  • : Vyome Holdings Enters Letter of Intent for Acquisition of Convertible Note (date Fundz recorded it)
  • : SEC 8-K (5.02): On August 27, 2026, Vyome Holdings, Inc. appointed Jerry Leonard as its Chief Financial Officer. Mr. Leonard will be providing services through a Consulting Agreement with ClearbridgeCFO, LLC, effective September 1, 2026. The agreement stipulates a consulting fee of $15,000 per month and has an initial term of one year, auto-renewing thereafter unless terminated under specific conditions. Notably, Mr. Leonard has extensive experience, previously serving as CFO for various firms and is the founder of ClearBridge, underscoring a strategic move to bolster Vyome's financial leadership as it navigates its operational growth.
  • : SEC 8-K (2.02): On August 25, 2026, Vyome Holdings, Inc. announced its financial results for the second fiscal quarter ending June 30, 2026. The press release details the company's performance metrics, which are crucial for investors and stakeholders to assess financial health and operational success. Such announcements typically influence stock prices and investor sentiment. This event is critical for understanding the company's ongoing financial condition and operational performance as it moves through its fiscal year.
  • : SEC 8-K (1.01): On February 20, 2026, Vyome Holdings, Inc. entered into a Notes Purchase and Exchange Agreement with LiveChain, Inc. and Remus Capital Series B II, L.P. to acquire senior secured convertible notes from Sociometric Solutions, Inc. for $5,765,000. In exchange, Remus will receive 211,200,844 shares of LICH common stock, which represents 25% of LICH's common stock prior to closing. This agreement also includes provisions for additional shares to be reserved for employee compensation. An amendment to the Agreement was made on February 25, 2026, to update certain terms pertaining to the transaction. The strategic implications of this acquisition aim to bolster LICH's operations and financial standing, ensuring that Humanyze remains viable for servicing existing obligations.
  • : SEC 8-K (7.01): Vyome Holdings, Inc. has filed a Form 8-K to disclose that company representatives will be presenting at investor conferences. This disclosure includes materials attached as Exhibit 99.1, which contains pertinent information about the company's operations and performance. The relevant date of the events described in the filing is February 13, 2026, which is the same day as this report. This presentation aims to provide investors with updated information regarding the company's activities and strategies, ensuring compliance with Regulation FD.
  • : SEC 8-K (7.01):
  • : SEC 8-K (8.01): On January 27, 2026, Reshape Lifesciences Inc. announced key findings from an independent U.S. market assessment and valuation analysis of its lead clinical candidate VT-1953, which is aimed at treating symptoms of malignant fungating wounds. The press release is an important communication regarding the commercial forecast and potential market impact of VT-1953, as it highlights the strategic implications of their clinical developments. This press release was attached as Exhibit 99.2 to the Form 8-K, showcasing the company's proactive engagement with stakeholders about product developments.
  • : SEC 8-K (1.01):
  • : SEC 8-K (1.01): On December 17, 2025, Vyome Holdings, Inc. entered into a binding letter of intent with LiveChain, Inc. (LICH) and Remus Capital Series B II, L.P. regarding a proposed transaction where LICH, an indirect subsidiary of Vyome, will acquire a senior secured convertible note from Sociometric Solutions, Inc. d/b/a Humanyze, held by Remus. As part of this transaction, LICH will issue shares to Remus representing 25% of the fully diluted common stock of LICH. The agreement outlines the formation of a new subsidiary by LICH, named Newco Sub, which will finalize the Note Purchase and Exchange Agreement. This strategic move aims to enhance LICH’s financial position by acquiring significant assets from Humanyze.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Leadership

  • Jerry Leonard, Chief Financial Officer
  • Manoj Sharma, Senior Associate Scientist
  • Akshay Kumar, Analytical Scientist
  • Nitin Gaur
  • Srivani Mukkamala, Program Management
  • Anubhuti Jain, Scientist II
  • Pardeep Kumar, Sr. Manager
  • Tamara Agajanov McNally, Vice President
  • Richard Fahrner, Chief Technology Officer

Verified email and direct lines for Vyome Holdings’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Companies similar to Vyome Holdings

About Vyome Holdings: questions and answers

What does Vyome Holdings do?

Vyome is a clinical-stage healthcare holding company focusing on transformative therapies for patients with immuno-inflammatory conditions. They are building a premier platform spanning the US-India innovation corridor. Vyome aims to leverage its clinical-stage assets to create shareholder value in a cost-efficient manner.

Where is Vyome Holdings headquartered?

Vyome Holdings is headquartered in San Clemente, California, United States.

How many employees does Vyome Holdings have?

Vyome Holdings has about 19 employees.

Who leads Vyome Holdings?

Tamara Agajanov McNally is a Vice President at Vyome Holdings.

What is the latest news on Vyome Holdings?

On Sep 14, 2026, Vyome Appoints Jerry Leonard as Chief Financial Officer

Is Vyome Holdings a public company?

Yes. Vyome Holdings is publicly traded under the ticker HIND.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Vyome Holdings across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.